Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports Based on WHO Pharmacovigilance Database, VigiBase
Therapeutic Innovation & Regulatory Science · 2025
DOI: 10.1007/s43441-025-00852-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2025. Verfasst von Min-Jung Lim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Pharmacovigilance, Product Surveillance, Postmarketing, Genetic Therapy, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Safety assessments of gene therapy medicinal products (GTMPs) require comprehensive data collection from a variety of sources to ensure thorough evaluation. This study aimed to analyze the characteristics of adverse event (AE) reports for GTMPs, dividing them into Solicited Reports (SRs) and Unsolicited Reports (USRs), and to provide insights for developing effective pharmacovigilance strategies customized for GTMPs. METHODS: Individual case safety reports (ICSRs) collected from GTMPs were retrieved using VigiBase. We identified GTMPs approved by the United States Food and Drug Administration (US FDA) and/or European Medicines Agency (EMA) by December 31, 2022, and maintained their approval status as of July 28, 2023. Descriptive statistics were used to summarize the ICSRs’ characteristics. The reported AEs were classified into System Organ Classes (SOCs) and Preferred Terms (PTs). RESULTS: A total of 12,180 ICSRs for 13 GTMPs were retrieved from VigiBase. Of these, 27.6% were SR and 72.4% USR. As the number of ICSRs increased, the proportion of USR tended to increase. Compared to the SR, consumer reports were much less common in the USR. The majority of the reported events were serious in both groups. In the drug-AE pairs, cytokine release syndrome and pyrexia were the most commonly reported in both the SR and USR. Meanwhile the most frequently reported SOCs were “Investigations” in SR and “Nervous system disorders” in USR, respectively. CONCLUSIONS: Our study highlights the need for robust pharmacovigilance measures customized for GTMPs. The continued refinement of pharmacovigilance strategies customized for GTMPs is essential to ensure their safe and effective use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea.
- Department of Pharmaceutical Industry, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea.
- Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea. shin.jy@skku.edu.
- Department of Pharmaceutical Industry, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea. shin.jy@skku.edu.
Zitieren
APA
Lim, M. J., Paek, E., & Shin, J. Y. (2025). Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports Based on WHO Pharmacovigilance Database, VigiBase. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-025-00852-5
Vancouver
Lim MJ, Paek E, Shin JY. Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports Based on WHO Pharmacovigilance Database, VigiBase. Therapeutic Innovation & Regulatory Science. 2025. doi:10.1007/s43441-025-00852-5
BibTeX
@article{Lim2025,
author = {Lim, Min-Jung and Paek, Eunah and Shin, Ju-Young},
title = {Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports Based on WHO Pharmacovigilance Database, VigiBase},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2025},
doi = {10.1007/s43441-025-00852-5}
}
EUVIMED